Literature DB >> 29653129

Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases.

Stephen P Newman1.   

Abstract

The repurposing of drug delivery by the pulmonary route has been applied to treatment and prophylaxis of an increasingly wide range of respiratory diseases. Repurposing has been most successful for the delivery of inhaled bronchodilators and corticosteroids in patients with asthma and chronic obstructive pulmonary disease (COPD). Repurposing utilizes the advantages that the pulmonary route offers in terms of more targeted delivery to the site of action, the use of smaller doses, and a lower incidence of side-effects. Success has been more variable for other drugs and treatment indications. Pulmonary delivery is now well established for delivery of inhaled antibiotics in cystic fibrosis (CF), and in the treatment of pulmonary arterial hypertension (PAH). Other inhaled treatments such as those for idiopathic pulmonary fibrosis (IPF), lung transplant rejection or tuberculosis may also become routine. Repurposing has progressed in parallel with the development of new drugs, inhaler devices and formulations.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha1 antitrypsin; Asthma; Chronic obstructive pulmonary disease; Cyclosporine; Cystic fibrosis; Mucoactive agents; Tobramycin

Mesh:

Substances:

Year:  2018        PMID: 29653129     DOI: 10.1016/j.addr.2018.04.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  20 in total

Review 1.  The emergence of nanoporous materials in lung cancer therapy.

Authors:  Deepika Radhakrishnan; Shan Mohanan; Goeun Choi; Jin-Ho Choy; Steffi Tiburcius; Hoang Trung Trinh; Shankar Bolan; Nikki Verrills; Pradeep Tanwar; Ajay Karakoti; Ajayan Vinu
Journal:  Sci Technol Adv Mater       Date:  2022-07-20       Impact factor: 7.821

2.  Therapeutic Delivery of Nitric Oxide Utilizing Saccharide-Based Materials.

Authors:  Yun Qian; Rajnish Kumar; Manjyot Kaur Chug; Hamed Massoumi; Elizabeth J Brisbois
Journal:  ACS Appl Mater Interfaces       Date:  2021-10-29       Impact factor: 10.383

3.  Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.

Authors:  Carina Conzelmann; Janis A Müller; Lukas Perkhofer; Konstantin Mj Sparrer; Alexander N Zelikin; Jan Münch; Alexander Kleger
Journal:  Clin Med (Lond)       Date:  2020-08-30       Impact factor: 2.659

Review 4.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

5.  Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2018-09-14       Impact factor: 5.875

6.  In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs.

Authors:  Alan J Hibbitts; Joanne M Ramsey; James Barlow; Ronan MacLoughlin; Sally-Ann Cryan
Journal:  Nanomaterials (Basel)       Date:  2020-06-27       Impact factor: 5.076

Review 7.  Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis.

Authors:  Giulio Cabrini; Alessandro Rimessi; Monica Borgatti; Ilaria Lampronti; Alessia Finotti; Paolo Pinton; Roberto Gambari
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

Review 8.  Multifunctional Nanocarriers for Lung Drug Delivery.

Authors:  Jorge F Pontes; Ana Grenha
Journal:  Nanomaterials (Basel)       Date:  2020-01-21       Impact factor: 5.076

Review 9.  Recent Strategic Advances in CFTR Drug Discovery: An Overview.

Authors:  Marco Rusnati; Pasqualina D'Ursi; Nicoletta Pedemonte; Chiara Urbinati; Robert C Ford; Elena Cichero; Matteo Uggeri; Alessandro Orro; Paola Fossa
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

10.  Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis.

Authors:  Xin Chang; Lei Xing; Yi Wang; Chen-Xi Yang; Yu-Jing He; Tian-Jiao Zhou; Xiang-Dong Gao; Ling Li; Hai-Ping Hao; Hu-Lin Jiang
Journal:  Sci Adv       Date:  2020-05-27       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.